January 28, 2022 PAO-01-22-R250-13
As a stop on Pharma's Almanac's The Road to 50 States trans-American trip, Reginald Kidd and Ashik Pavagadhi of IDT Biologika talk to Nigel about the company's historic milestone and how cell and gene therapy will shape the future of healthcare.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
IDT Biologika is a global biopharmaceutical contract development and manufacturing organization that specializes in the production of innovative live viral vaccines, viral vectors for gene and immune therapeutics, oncolytic viruses and virus-like particles. They offer clients a single source CDMO partner with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. This includes process development, drug substance manufacturing, sterile dosage filling, primary and secondary packaging, quality control and analytics. IDT Biologika handles every step in manufacturing and packaging of small clinical batches and of large scale commercial products.